Adropin

What is Adropin?

Adropin is a secreted peptide hormone encoded as a 76-amino-acid precursor by the ENHO ("Energy Homeostasis Associated") gene. The first 33 residues are a secretory signal sequence that is cut off, so the form that circulates — and the form used in animal studies — is the 43-amino-acid fragment known as adropin 34-76. It was first identified in 2008 as a liver- and brain-derived factor regulating energy homeostasis and macronutrient adaptation. Since then, research has expanded to show roles in glucose metabolism, insulin sensitivity, endothelial function (partly via eNOS upregulation), and cardiac fuel metabolism. Adropin is primarily a research molecule and biomarker — it is not available as a therapeutic product, has no clinical trial program as a drug, and is not FDA-approved for any indication. Its relevance to the wellness and peptide community is largely aspirational: circulating adropin levels correlate with metabolic health, but exogenous adropin has not been validated in humans.

What Adropin Is Investigated For

Adropin's research footprint is dominated by its role as a metabolic biomarker — low circulating adropin associates with obesity, type 2 diabetes, NAFLD, and coronary artery disease across several meta-analyses, and higher levels generally track better cardiovascular outcomes. The pattern is not universal. A meta-analysis found adropin higher, not lower, in gestational diabetes than in normal pregnancy, and in a five-year study of older adults with hypertension, higher adropin predicted greater blood-pressure variability. Heart failure is genuinely contested: a 2011 study of 56 patients found plasma adropin climbing with NYHA class, while later reviews group heart failure with the low-adropin conditions and a 2023 study found dapagliflozin raising adropin as heart failure improved. Treating adropin as a simple low-equals-sick dial oversimplifies it. The strongest biology is mechanistic: adropin upregulates endothelial nitric oxide synthase (eNOS) via VEGFR2–PI3K–Akt and VEGFR2–ERK1/2 pathways, improves insulin sensitivity in rodent models, and has neuroprotective effects in ischemia-reperfusion injury. What adropin is not: a validated therapeutic. There is no approved adropin drug, no registered clinical trial of exogenous adropin for any indication, no established dose, and no human safety data. The "take adropin for metabolic health" framing that appears in peptide marketing extrapolates from biomarker correlations and preclinical data — real signals, but not the same as proven human therapeutic effect.

History & Discovery

Adropin was first identified and named in 2008 by Andrew Butler's group (then at the Pennington Biomedical Research Center) in a paper in Cell Metabolism that characterized a previously uncharacterized gene — Energy Homeostasis Associated, or ENHO — whose hepatic expression was modulated by diet composition in mice. The team showed that the protein product, a 76-amino-acid secreted peptide they christened adropin (from Latin *aduro*, to set fire to, and *pinguis*, fat), was induced by high-fat feeding and suppressed by chronic obesity, and that a synthetic version of the secreted fragment, adropin 34-76 — supplied by Biomeasure/Ipsen under a sponsored research agreement — reversed fatty liver and insulin resistance in diet-induced obese mice. The framing — a liver-derived energy-homeostasis factor with metabolic action — set the initial research agenda. A second pivotal paper followed in 2010 (Lovren et al., *Circulation*), reframing adropin as a hepatokine regulator of endothelial function via VEGFR2/Akt-mediated eNOS upregulation; this expanded the field beyond pure metabolism into vascular biology. The subsequent fifteen years have been dominated by biomarker work — observational studies linking low circulating adropin to obesity, type 2 diabetes, NAFLD, atherosclerosis, and adverse cardiovascular outcomes — alongside mechanistic preclinical work in cardiac fuel metabolism, neuroprotection, and most recently testicular and reproductive biology. Despite this breadth, adropin has never crossed into clinical drug development: there is no registered human trial of exogenous adropin administration. The closest step toward a therapy is intellectual property: in April 2024 the US Patent Office granted Saint Louis University and the Department of Veterans Affairs a patent, with Butler as lead inventor, covering the administration of exogenous adropin to people with or at risk of cognitive decline. A patent is a long way from a drug, but it signals where the discoverers think the opportunity lies.

How It Works

Adropin is a hormone your liver and brain make to help regulate energy balance, blood sugar, and blood vessel function. People with obesity, diabetes, or heart disease tend to have lower adropin levels, and animal studies show that giving adropin improves insulin sensitivity and blood vessel health. But no one has successfully turned adropin into a drug — it's currently a research marker, not a treatment.

Adropin is encoded by the ENHO gene as a 76-amino-acid precursor whose secreted, bioactive fragment is adropin 34-76 (43 amino acids). It is expressed primarily in liver and brain and detectable in serum, kidney, heart, pancreas, small intestine, and vascular endothelium. In endothelial cells, adropin upregulates eNOS expression through the VEGFR2–PI3K–Akt and VEGFR2–ERK1/2 pathways, increasing nitric oxide bioavailability and vasodilation. In hepatocytes and skeletal muscle, adropin modulates fatty acid oxidation, glucose uptake, and insulin sensitivity — overexpression in diet-induced obese mice improves insulin sensitivity and reduces diabetes markers. In the brain, adropin reduces the leakiness of the blood-brain barrier under ischemic conditions. The cell-culture study most often cited for this found the effect was not explained by protecting junction proteins, and traced it instead to blocking the ROCK-MLC2 contraction pathway in brain endothelial cells. In live mice, later work did show preserved tight-junction proteins and lower MMP-9 activity after stroke — and showed the protective effect disappears entirely in mice lacking eNOS, which pins it on nitric oxide signaling. A candidate receptor, GPR19, has been proposed but not universally accepted. A September 2026 review that graded the evidence pathway by pathway concluded that GPR19 remains a disputed candidate, while the best-supported partner in brain tissue is a different molecule — NB-3 (contactin-6), a Notch ligand that adropin physically associates with. Mice lacking adropin show the same movement and coordination problems as mice lacking NB-3. Adropin levels are regulated by nutritional state (rising with fat intake, falling with energy excess in chronic overfeeding) and, in mice, by estrogen: removing the ovaries lowers liver adropin, and estradiol triples its expression in cultured liver cells. In people, the clearest sex difference is simply that men tend to have higher levels than women. A 2026 review also positioned adropin as a regulator of testicular function, summarizing rodent work in which it stimulated testosterone production in Leydig cells and increased germ-cell proliferation by suppressing apoptosis and oxidative stress. The same year, work in human ovarian granulosa cells pointed the other way — adropin reduced their proliferation and promoted apoptosis — so the reproductive picture is tissue-specific rather than uniformly pro-fertility, and early.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Adropin:

• 01Measurement is now the field's own stated bottleneck. A 2026 review argues that progress depends on receptor definition, assay harmonization and delivery chemistry rather than on more disease associations, naming peptide instability, blood-brain-barrier delivery, non-standardized immunoassays and incomplete receptor pharmacology as the barriers. Published adropin concentrations differ by orders of magnitude between studies, which makes cross-study comparison of absolute values unsafe.
• 02Serum protein and gene expression can point in opposite directions. A 2026 study of 107 people found serum adropin elevated in type 2 diabetes relative to prediabetes and controls, while ENHO gene expression was highest in prediabetes and lowest in type 2 diabetes. Nothing on the page's biomarker map explains how a hormone can be high in blood while its transcript falls.
• 03Whether the biomarker associations are causal at all. The closest thing to causal human evidence is a 2026 genetic study of 300 adults in which a higher ENHO genetic-risk score tracked lower adropin and greater early vascular aging, with the adropin-to-endothelin-1 imbalance statistically mediating about half of that association. One genetic study in 300 people is a starting point, not an answer.
• 04There is no standardized adropin assay. Commercial ELISA kits disagree on absolute concentrations by orders of magnitude between publications, and pooled analyses report statistical heterogeneity above 99%. Until measurement is standardized, comparing adropin values across studies — let alone setting a clinical cut-off — is not defensible.
• 05The biomarker literature contains contradictions that have not been reconciled. Adolescents with biopsy-confirmed fatty liver disease showed no reduction in serum adropin at all, even though adults with the same diagnosis show a clear reduction. Whether this reflects age, assay differences, or genuinely different biology is unknown.
• 06Receptor identity remains unsettled. GPR19 has been proposed as the adropin receptor in several studies, but the data are inconsistent and the field has not converged. Without a confirmed receptor, downstream signaling characterization remains incomplete and developing receptor-targeted small molecules is impossible.
• 07Whether exogenous administration replicates endogenous-elevation correlations is unknown. The biomarker literature mostly links higher endogenous adropin with better metabolic and cardiovascular outcomes — though the direction reverses in heart failure and gestational diabetes — but it is unproven that raising adropin pharmacologically delivers the same benefits. Biomarker correlations and therapeutic effects routinely diverge.
• 08No human pharmacokinetic profile exists. Half-life, bioavailability by any route, distribution volume, clearance pathways, and dose-response relationships in humans are all uncharacterized.
• 09The testicular and reproductive-axis role flagged by the 2026 review is intriguing but early — mechanistic detail, magnitude of effect, and clinical relevance to fertility, testosterone, or spermatogenesis are unestablished.
• 10Causal direction in the SGLT2/DPP-4 inhibitor adropin elevation finding is unresolved. Do these drugs work partly through adropin elevation, or does adropin simply rise as a downstream marker of improved metabolic state? Designed-causal experiments are needed.
• 11Sex differences are underexplored. Estrogen modulates adropin in humans, and the testicular biology is by definition male-specific, but most observational studies have not stratified analyses by sex with adequate power.
• 12Long-term safety of any exogenous adropin elevation — even via approved metabolic drugs that incidentally raise it — has not been specifically studied as an adropin effect.

Forms & Administration

Adropin is not available as an approved therapy. Research applications use recombinant adropin administered parenterally in animal studies. For clinical relevance, the practical path to raising endogenous adropin is lifestyle-mediated — weight loss, improved nutritional patterns, and exercise all tend to raise circulating levels. A 2026 randomized trial added a pharmacologic signal: in 100 adults with inadequately controlled type 2 diabetes on stable metformin, randomized open-label to twelve weeks of empagliflozin 10 mg or sitagliptin 100 mg daily, adropin rose in both arms (291 to 362 pg/mL and 299 to 358 pg/mL, p < .001 for the time effect), suggesting some approved metabolic drugs may elevate endogenous adropin as a downstream effect — though this is an associative finding, not evidence that adropin elevation drives those drugs' benefits.

Common Questions

Who Adropin Is NOT For

Drug & Supplement Interactions

There are no documented drug interactions for exogenous adropin in humans, because no clinical trial of exogenous adropin has been completed. Theoretical considerations dominate. The most direct interaction concern is additive nitric-oxide-mediated vasodilation: adropin upregulates eNOS in endothelium, so combining pharmacologic adropin with nitrates, PDE5 inhibitors (sildenafil, tadalafil), or other strong vasodilators could in principle potentiate hypotension. Adropin's overlap with insulin-sensitizing pathways also raises the question of additive effects with metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin — a 2026 randomized trial in 100 patients showing empagliflozin and sitagliptin both raise endogenous adropin in type 2 diabetes, whose authors read the rise as a treatment-responsive biomarker rather than a drug-specific effect, hints at meaningful pathway crosstalk, though direction of causality and clinical significance remain unclear. Other approved drugs move adropin in both directions: liraglutide raised serum adropin over twelve weeks in newly diagnosed type 2 diabetes with fatty liver, and dapagliflozin raised it by up to 26.6% over six months in diabetic heart failure, while statin treatment was associated with lower plasma adropin in a large human-tissue study. Finally, the VEGFR2 signaling node adropin engages is also targeted by oncology drugs (anti-VEGF antibodies, multikinase inhibitors); any clinical adropin program would need to think carefully about that intersection. None of this should be read as established interaction data — it is the honest list of plausible flags given current mechanistic understanding.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions